Oslo, Norway, 5 February 2026. Reference is made to the stock exchangeannouncement by EXACT Therapeutics AS (the “Company”, Euronext Growth ticker:EXTX), a clinical-stage precision medicine company, published at 09:17 todayon5 February 2026. In the earlier announcement, it was incorrectly stated that the remainingwarrants holders may exercise their warrants within 21 February 2026. Thecorrect final date for the warrants exercise is 26 February 2026.
About EXACT Therapeutics:EXACT Therapeutics is a clinical-stage precision medicine company utilizingthepower of ultrasound to activate the proprietary drug PS101 and enhance theclinical benefit of oncology therapies. PS101 has a unique mode of action andmay be combined with a wide range of therapeutic agents within oncology andacross a multitude of other indications, including brain diseases. EXACTTherapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Furtherinformation may be found here:www.exact-tx.com
For further information, please contact:Per WaldayCEO EXACT TherapeuticsEmail: per.walday@exact-tx.com
https://newsweb.oslobors.no/message/664935